Recent Progress in Systemic Therapy for Advanced Hepatocellular Carcinoma.

ABSTRACT: Patients with advanced hepatocellular carcinoma (HCC) have several systemic treatment options. There are many known risk factors for HCC, and although some, such as hepatitis C, are now treatable, others are not. For example, metabolic dysfunction-related chronic liver disease is increasing in incidence and has no specific treatment. Underlying liver disease, drug resistance, and an increasing number of treatment options without specific biomarkers are all challenges in selecting the best treatment for each patient. Conventional chemotherapy is almost never used for advanced-stage disease, which instead is treated with immunotherapy, tyrosine kinase inhibitors, and VEGF inhibitors. Immune checkpoint inhibitors targeting various receptors have been or are currently undergoing clinical evalu

SUBMITTER: Sadagopan N 

PROVIDER: S-EPMC10816205 | biostudies-literature | 2024 Jan

REPOSITORIES: biostudies-literature